Addex Announces Publication of Preclinical Data Supporting Potential of mGlu7 Negative Allosteric Modulators to Transform Anxiety and Fear-Related Disorder Treatment

Data published in Molecular PsychiatryAd Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, February 3, 2026-Addex Therapeutics (SIX: ...
Healio

Allosteric modulator nonsuperior to placebo in Parkinson’s disease

Please provide your email address to receive an email when new articles are posted on . Change from baseline in gait variability did not differ between groups, regardless of cognitive load. Treatment ...
Seeking Alpha

Addex and Indivior Select Clinical Candidates from GABAB Positive Allosteric Modulator Research Collaboration

Geneva, Switzerland, August 27, 2024 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators ...
Drug Target Review

Targeting mGlu7 could lead to new anxiety and PTSD treatments

Explore innovative anxiety and PTSD treatments with Addex Therapeutics' groundbreaking research on mGlu7 modulators.
FierceBiotech

Gain hopes to prove Parkinson's drug's potential next year after phase 1 win for allosteric modulator

Gain Therapeutics has set its sights on proving the effectiveness of its Parkinson’s disease therapy next year after the brain-penetrant small molecule demonstrated “peripheral target engagement” in a ...
Seeking Alpha

Axsome Therapeutics Acquires Subtype Selective GABA-A Receptor Positive Allosteric Modulator AZD7325 for the Treatment of Epilepsy

NEW YORK, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced ...
Monthly Prescribing Reference

Negative Allosteric Modulator Candidate Misses Endpoints in Social Anxiety Disorder Trial

Neuphoria’s social anxiety disorder program will be discontinued based on the results from the AFFIRM-1 trial. Topline results were announced from a phase 3 trial evaluating BNC210 in patients with ...
Nasdaq

Addex Partner Indivior Advances GABAB Positive Allosteric Modulator Program Successfully Through IND Enabling Studies

Geneva, Switzerland, May 12, 2025-Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for ...